Skip to main content
. 2023 Dec 28;12:e83103. doi: 10.7554/eLife.83103

Figure 2. Elevated MCV anemia in MDS mice is partially reversed by DFP.

Circulating RBC count (A), hemoglobin (B), MCV (C), reticulocyte count (D), platelet count (E), WBC count (F), neutrophil count (G), lymphocyte count (H), and monocyte count (i) in WT, MDS, and DFP-treated MDS mice (n=10–14 mice/group) analyzed after 1 month of treatment. *p<0.05 vs. WT; **p<0.01 vs. WT; ***p<0.001 vs. WT; ****p<0.0001 vs. WT; &p<0.05 vs. MDS; &&p<0.01 vs. MDS. Abbreviations: WT = wild type; MDS = myelodysplastic syndrome; DFP = deferiprone; RBC = red blood cell; MCV = mean corpuscular volume; WBC = white blood cell.

Figure 2—source data 1. Source data for circulating cell counts and other parameters in wild type (WT), myelodysplastic syndrome (MDS), and DFP-treated MDS mice.

Figure 2.

Figure 2—figure supplement 1. DFP resulted in similar effects on hemoglobin in male and female myelodysplastic syndrome (MDS) mice.

Figure 2—figure supplement 1.

Similarly elevated hemoglobin is observed in male and female DFP-treated MDS mice (n=4–6 male mice/group and n=4–9 female mice/group). *p<0.05 vs. control; Con = control; DFP = deferiprone.
Figure 2—figure supplement 1—source data 1. Source data for hemoglobin in male and female myelodysplastic syndrome (MDS) and DFP-treated MDS mice.